The increasingly competitive weight-loss therapeutic space was shaken up a bit on 29 September when structure-based drug design firm Structure Therapeutics, Inc. unveiled early data indicating that its oral GLP-1 receptor agonist can yield significant weight loss quickly and with a tolerability profile that should be competitive against injectable agents currently in great demand.
Key Takeaways
-
Structure Therapeutics’ oral GLP-1 receptor agonist shows significant weight loss and good tolerability in a small, early-stage study.
San Francisco-based Structure grossed $161.1m in an initial public offering this past February – at a time of constrained IPO...